The emerging toxicity profiles of anti–CTLA-4 antibodies across clinical indications
AM Di Giacomo, M Biagioli, M Maio - Seminars in oncology, 2010 - Elsevier
The promising new class of immunomodulating antibodies directed against cytotoxic T-
lymphocyte antigen-4 (CTLA-4) has been extensively tested in clinical trials and found to be
active against cutaneous melanoma and other tumor histotypes. Inhibition of CTLA-4
characteristically induces well-identified side effects for which the definition “immune-related
adverse events”(irAEs) has been proposed. IrAEs mainly include colitis/diarrhea, dermatitis,
hepatitis, and endocrinopathies; uveitis, nephritis, and inflammatory myopathy also have …
lymphocyte antigen-4 (CTLA-4) has been extensively tested in clinical trials and found to be
active against cutaneous melanoma and other tumor histotypes. Inhibition of CTLA-4
characteristically induces well-identified side effects for which the definition “immune-related
adverse events”(irAEs) has been proposed. IrAEs mainly include colitis/diarrhea, dermatitis,
hepatitis, and endocrinopathies; uveitis, nephritis, and inflammatory myopathy also have …